更新于：2024-05-01
Ephedrine Hydrochloride
盐酸麻黄碱
更新于：2024-05-01
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2021-06-14), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C10H15NO |
InChIKeyKWGRBVOPPLSCSI-WPRPVWTQSA-N |
CAS号299-42-3 |
查看全部结构式(2)
关联
80
项与 盐酸麻黄碱 相关的临床试验Effect of Ephedrine, Phenylepinephrine, and Norepinephrine on Myometrial Contractility in Pregnant People With Type II and Gestational Diabetes During Cesarean Section: An In-vitro Study
A Study on the Appropriate Dosage of Vasopressors to Maintain Adequate Cerebral Blood Flow During Surgery and Anesthesia in Neonates and Infants
Could Ephedrine Replace Dexmedetomidine for Prevention of Shivering in Women Undergoing Cesarean Section Under Spinal Anaesthesia
100 项与 盐酸麻黄碱 相关的临床结果
登录后查看更多信息
100 项与 盐酸麻黄碱 相关的转化医学
登录后查看更多信息
100 项与 盐酸麻黄碱 相关的专利（医药）
登录后查看更多信息
200
项与 盐酸麻黄碱 相关的文献（医药）2023-12-04Biomedical chromatography : BMC
Prediction and analysis of quality markers for Chuantieling gel patches based on HPLC fingerprinting and network pharmacology.
Article
作者: Lixin Du ; Huiling Lu ; Yifei Xiao ; Zhihua Guo ; Ya Li
The Chuantieling gel patch (CGP), a traditional Chinese medicine compound, is an external treatment for asthma. It has shown remarkable effectiveness in alleviating asthma-related airway hyperresponsiveness and inflammation. Nevertheless, there is currently no information available regarding the analysis of quality markers for CGP, and there is a need for further improvement in quality control research. In this study, we developed an HPLC fingerprinting method for CGP and conducted a comprehensive methodological investigation. We assessed the similarity among 10 batches of CGP, identified common peaks, and quantified the content of seven major quality markers. Furthermore, we built a network pharmacology-based 'active ingredients-targets-pathways-diseases' network to forecast the potential mechanisms of action for the primary active components in asthma treatment. Our findings demonstrated that the developed CGP fingerprinting and content determination methods were consistent and trustworthy. We verified the existence of 25 shared peaks and successfully identified 7 chromatographic peaks, including sinigrin thiocyanate, ephedrine hydrochloride, methyleugenol, imperatorin, cinnamaldehyde, emodin, and 6-gingerol, using reference standards. The network pharmacology analysis suggested that these seven active components may target proteins such as STAT3 (signal transducer and activator of transcription 3), MAPK3 (mitogen-activated protein kinase 3), and TP53 (tumor protein P53) and influence various diseases through pathways including cancer pathways, hepatitis B, and PI3K-Akt (phosphoinositide 3-kinase-protein kinase B) signaling. This study provides insight into the complex multicomponent composition of CGP, and the predictive analysis through network pharmacology sets the stage for uncovering the mechanisms responsible for the therapeutic effects of CGP.
2023-06-22AAPS PharmSciTech
Detection and Identification of an Unknown Impurity in Ephedrine HCl 5 mg/mL Cyclic Olefin Syringes: Formulation Development.
Article
作者: Ellen A Kok ; Daphne den Besten-Bertholee ; Stefan van Berkel ; Karin H M Larmené-Beld
An unknown impurity was detected in in-house prepared ephedrine hydrochloride (HCl) 5 mg/mL prefilled sterilized syringes when applying a stability-indicating British Pharmacopoeia 2018 impurity method for ephedrine injection. Ultraviolet, chromatographic, mass spectral, and physicochemical methods were combined to identify the unknown impurity. The unknown impurity was identified as methcathinone, which is generated from ephedrine drug substance through an oxidation reaction. A formulation study, in which different process adjustments were tested, was carried out to reduce the amount of unknown impurity. Nitrogen gassing in combination with 0.05 M citrate buffer addition proved to be the most potent process adjustment in reducing methcathinone formation in ephedrine HCl 5 mg/mL prefilled sterilized syringes after 4 months of storage in the dark at room temperature (20 °C ± 5 °C). More detailed research on the long-term stability of the reformulated ephedrine HCl drug product is currently underway, with promising results for up to 9 months gathered already.
2023-06-01Saudi journal of biological sciences
Stability of (1R,2S)-(-)-Ephedrine hydrochloride in Candida albicans-inoculated urine and blood samples
Article
作者: Khaled, Jamal M. ; Alharbi, Naiyf S. ; Al-Huwaymil, Rayan M. ; Kadaikunnan, Shine ; Alobaidi, Ahmed S. ; Alfalih, Abdullah M.
The stability of drugs in biological evidence during collection and storage is of particular concern in forensic investigations. Microbes in the samples and other elements are an essential component of these investigations. In the current study, the HPLC method was used to examine the stability of (1R, 2S)-(-)-Ephedrine hydrochloride in plasma and urine samples inoculated with C. albicans after storage at 37 °C for 48 h and -20 °C for six months. In the stability experiment, MIC50% of (1R, 2S)-(-)-Ephedrine hydrochloride was applied according to MIC and MFC that were determined in this work. This drug had MIC and MFC of 50 and 100 ppm, respectively. In HPLC analysis, the standard (1R, 2S)-(-)-Ephedrine hydrochloride had a retention time of 1.63 and was used to identify this drug in samples that had or had not been exposed to C. albicans. The findings demonstrated that within 48 h at 37 °C, C. albicans had an impact on the drug concentration (10% and more than 15%, respectively, were lost in plasma and urine samples inoculated with C. albicans). In plasma samples, the drug content remained stable at -20 °C for three months, although it degraded in urine samples after one month. In plasma and urine samples, the concentration reduction had surpassed 70% and 50% by the sixth month, respectively. The results of this investigation show that C. albicans can change the stability of (1R, 2S)-(-)-Ephedrine hydrochloride in plasma and urine samples that contain MIC50% of Ephedrine hydrochloride.
100 项与 盐酸麻黄碱 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 鼻塞 | 批准上市 | - | - |
| 哮喘 | 批准上市 | - | - |
| 慢性阻塞性肺疾病 | 批准上市 | - | - |
| - | 批准上市 | 日本 更多 | |
| 低血压 | 批准上市 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 53 | Saline Placebo (Saline Placebo) | 簾鬱膚窪淵蓋艱鏇網廠(繭衊醖膚積築衊鏇齋願) = 膚築觸觸鏇鹹網衊窪觸 糧淵構齋鏇築淵獵窪膚 (簾遞襯觸顧膚廠淵壓簾, 壓鑰鹹廠夢壓憲窪艱鑰 ~ 襯鹹顧觸構觸簾淵餘餘) 更多 | - | 2017-05-22 | ||
(IM Ephedrine) | 簾鬱膚窪淵蓋艱鏇網廠(繭衊醖膚積築衊鏇齋願) = 膚膚築醖醖繭餘鬱蓋齋 糧淵構齋鏇築淵獵窪膚 (簾遞襯觸顧膚廠淵壓簾, 顧窪觸選糧簾憲鹽鹹網 ~ 鑰憲顧醖構顧夢窪憲遞) 更多 | ||||||
N/A | 150 | RL solution preload + ephedrine | (廠壓簾窪鏇選製壓鹹願) = 齋鏇鬱膚選膚糧艱鹽鏇 蓋網糧艱築積鏇顧廠鏇 (簾願膚壓顧憲積壓糧夢 ) | - | 2012-01-01 | ||
Hemaxel preload + ephedrine | (廠壓簾窪鏇選製壓鹹願) = 糧蓋鬱鹽廠鹹顧願艱遞 蓋網糧艱築積鏇顧廠鏇 (簾願膚壓顧憲積壓糧夢 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用